查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961271

非处方止痛药市场－全球产业规模、份额、趋势、机会与预测：按药物类型、通路、地区和竞争格局划分，2021-2031年

Over-the-Counter Analgesics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球非处方止痛药市场预计将从 2025 年的 211.9 亿美元成长到 2031 年的 355.6 亿美元，复合年增长率为 9.01%。

这些药物被定义为非处方处方笺（OTC），旨在无需医生直接指导即可缓解轻度至中度疼痛、发烧和发炎。市场成长趋势主要受人口结构变化驱动，尤其是全球人口快速老化，导致慢性肌肉骨骼疾病的盛行率上升；此外，公共卫生政策的策略性转变，即鼓励自我治疗以降低成本，也是推动市场成长的重要因素。这一以消费者主导的医疗保健趋势得到了可靠的区域数据支持。例如，根据欧洲自我护理产业协会（AESC）的报告，预计到2025年，欧洲非处方药市场将成长8.4%，规模达到710亿美元。

市场概览
预测期 2027-2031
市场规模：2025年 211.9亿美元
市场规模：2031年 355.6亿美元
复合年增长率：2026-2031年 9.01%
成长最快的细分市场 医院药房
最大的市场 北美洲

然而，监管机构加强了对产品安全和预防误用的监管，这给市场带来了巨大的障碍。为了降低意外过量和成瘾等风险，监管机构正在收紧对标籤要求的执行力度，并限制包装尺寸，尤其是针对联合治疗。这些合规义务给製造商带来了沉重的负担，导致产品核可延迟和营运成本增加。因此，这些监管压力实际上延缓了创新止痛方案进入大众消费市场。

市场驱动因素

人口老化以及随之而来的与老龄化相关的疼痛疾病的增加，显着扩大了非处方止痛药的消费群。随着全球预期寿命的延长，慢性肌肉骨骼疾病（例如骨关节炎和腰痛）的盛行率不断上升，使得人们更需要便捷的长期疼痛管理策略。这群人越来越多地使用局部和全身性非类固醇消炎剂(NSAIDs) 来维持活动能力和生活质量，同时尽量减少就医次数，从而为成熟品牌创造了稳定的需求。行业领导者的财务成功也反映了这种持续的依赖性；根据 Haleon 公司于 2025 年 2 月发布的 2024 财年年度报告和 20-F 表格，该公司疼痛管理业务在该财年累计了26 亿英镑的收入。

同时，自我治疗和消费者主导医疗保健的全球趋势正在改变市场动态。在减轻医疗系统负担的需求以及数位健康素养提升的推动下，越来越多的消费者开始主动管理轻微疾病和急性疼痛。零售商店和电商平台便捷地提供各种止痛药，进一步促进了这一转变，使消费者能够进行主动健康管理。高销量也印证了这个趋势。欧洲自我护理产业协会（AESGP）在2024年度报告（2025年6月发布）中指出，上年度欧洲非处方药的销售量达到47亿盒。同样，利洁时集团（Reckitt Benckiser Group PLC）在2025年3月发布的报告显示，其医疗保健业务部门2024年的收入净额为58.82亿英镑。

市场挑战

对产品安全和误用风险日益严格的监管是全球非处方止痛药市场成长的主要障碍。监管机构正在执行严格的标籤要求并限制包装尺寸，尤其旨在降低诸如复方处方药意外过量服用等风险。这些合规要求迫使製造商投入大量资源来满足安全标准，导致营运成本增加，并占用了本应用于研发的资金。因此，新产品的核准流程延长，延缓了先进止痛方案进入大众市场的进程。

儘管消费者对自我治疗策略的依赖仍然很强，但监管瓶颈限制了产品的供应，从而直接阻碍了市场成长。近期消费者统计数据凸显了社会对便利止痛药物的高需求与商业化进展缓慢之间的差距。英国药品协会预测，到2025年，91%的成年人将使用非处方药治疗轻微健康问题。虽然如此广泛的使用表明市场具有巨大的扩张潜力，但严格的安全法规带来的财务和物流限制使得製造商无法完全满足市场需求，从而抑制了整个行业的收入成长。

市场趋势

随着消费者和医疗保健提供者寻求降低长期服用口服非类固醇抗发炎药 (NSAIDs) 带来的全身性风险，市场正经历着局部用药製剂的重大转变。这项转变的特点是，人们越来越倾向于选择经皮吸收贴片、凝胶和喷雾剂，这些製剂无需经过胃肠道或肝臟代谢即可提供局部镇痛。领先的经皮品牌的强劲表现证明了这种更安全的给药方式的商业性成功。例如，2024 年 10 月，久光製药公布其旗舰产品Salonpas)的销售额同比增长 17%，凸显了患者越来越多地依赖非全身性镇痛替代方案的趋势。

同时，在「洁净标示」运动的推动下，以及消费者对植物来源抗发炎药物日益增长的偏好，将天然植物成分融入止痛产品线的趋势愈发明显。製造商正积极收购和开发含有姜黄和薄荷醇等活性成分的产品，以吸引那些除了缓解症状外，更注重整体健康的健康意识消费者。这种向天然成分功效的策略转变，正为产业巨头带来实际的经济效益。例如，赛诺菲消费者保健部门在2024年7月发布的公布财报中显示，销售额增长了9.6%，这主要得益于其旗舰姜黄保健品牌家乐（Knorr）两位数的增长。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球非处方止痛产品市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物类型（乙酰胺酚、非类固醇消炎剂（NSAIDs）、水杨酸盐和其他镇痛药）
    • 分销通路（医院药局、零售药局、网路药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美非处方止痛药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲非处方止痛药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区非处方止痛药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲非处方止痛产品市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲非处方止痛药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球非处方止痛药市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services Inc
  • GSK plc
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • Merck & Co Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17073

The Global Over-the-Counter (OTC) Analgesics Market is projected to expand from a valuation of USD 21.19 Billion in 2025 to USD 35.56 Billion by 2031, reflecting a CAGR of 9.01%. These pharmaceutical formulations are defined as non-prescription treatments intended to relieve mild to moderate pain, fever, and inflammation without direct medical oversight. The market's upward trajectory is primarily driven by demographics, specifically a rapidly aging global population prone to chronic musculoskeletal issues, alongside a strategic pivot in public health policy that encourages self-medication to lower healthcare expenses. This trend toward consumer-led health management is reinforced by robust regional data; for instance, the Association of the European Self-Care Industry reported that the European OTC market grew by 8.4% in 2025, reaching a value of $71 billion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.19 Billion
Market Size 2031USD 35.56 Billion
CAGR 2026-20319.01%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

However, the market faces significant hurdles due to intensified regulatory scrutiny focused on product safety and the prevention of misuse. Regulatory authorities are increasingly enforcing strict labeling requirements and limiting pack sizes to mitigate risks such as accidental overdose or dependency, particularly regarding combination therapies. These compliance obligations place a heavy burden on manufacturers, resulting in delayed product approvals and escalated operational costs. Consequently, these regulatory pressures effectively decelerate the introduction of innovative pain relief solutions to the broader consumer market.

Market Driver

The expanding geriatric population and the concurrent rise in age-related pain conditions are significantly widening the consumer base for OTC analgesics. As global life expectancy rises, the prevalence of chronic musculoskeletal disorders, such as osteoarthritis and back pain, increases, creating a necessity for accessible, long-term pain management strategies. This demographic increasingly utilizes topical and systemic NSAIDs to preserve mobility and quality of life while minimizing the need for frequent physician consultations, thereby generating consistent demand for established brands. The financial success of category leaders reflects this sustained reliance; according to Haleon's 'Annual Report and Form 20-F 2024' published in February 2025, their Pain Relief business unit generated £2.6 billion in revenue for the fiscal year.

Concurrently, a decisive global trend toward self-medication and consumer healthcare autonomy is transforming market dynamics. Driven by the necessity to alleviate pressure on healthcare systems and supported by enhanced digital health literacy, consumers are increasingly managing minor ailments and acute pain independently. This shift is further fueled by the broad availability of various analgesic formats across retail and e-commerce platforms, which facilitates proactive health management. High sales volumes confirm this behavior; the Association of the European Self-Care Industry (AESGP) noted in its 'Annual Report 2024' (June 2025) that 4.7 billion packs of non-prescription medicines were sold in Europe the previous year. Similarly, Reckitt Benckiser Group PLC reported in March 2025 that its Health business unit achieved net revenue of £5,882 million in 2024.

Market Challenge

Increased regulatory scrutiny regarding product safety and the potential for misuse presents a formidable obstacle to the growth of the Global Over-the-Counter Analgesics Market. Authorities are rigorously implementing strict labeling mandates and restricting pack sizes to reduce risks such as accidental overdoses, specifically with combination formulas. These compliance requirements force manufacturers to allocate significant resources toward meeting safety standards, thereby driving up operational costs and diverting capital that would otherwise be used for research and development. As a result, the approval timeline for new products is extended, which delays the introduction of advanced pain relief options to the mass market.

This regulatory bottleneck directly inhibits growth by restricting product availability, even as consumer reliance on self-medication strategies remains strong. The gap between the high public demand for accessible pain management and the decelerated pace of commercialization is highlighted by recent consumption statistics. According to the Proprietary Association of Great Britain, 91% of adults reported utilizing over-the-counter products for minor health conditions in 2025. Although such extensive usage indicates immense potential for market expansion, the financial and logistical constraints imposed by stringent safety regulations prevent manufacturers from fully capitalizing on this demand, effectively moderating the sector's overall revenue progression.

Market Trends

The market is undergoing a significant shift toward topical formulations as both consumers and healthcare providers aim to reduce the systemic risks linked to long-term oral NSAID use. This transition is marked by a preference for transdermal patches, gels, and sprays, which provide targeted pain relief while bypassing gastrointestinal and hepatic metabolic processes. The commercial success of this safer delivery method is demonstrated by the strong performance of leading transdermal brands; for instance, Hisamitsu Pharmaceutical reported in October 2024 that revenue for its flagship product, Salonpas, rose by 17% year-on-year, highlighting the increasing patient reliance on non-systemic pain management alternatives.

In parallel, there is a marked integration of natural and botanical ingredients into analgesic product lines, fueled by the "clean label" movement and growing consumer preference for plant-based anti-inflammatory options. Manufacturers are actively acquiring or developing products containing agents such as turmeric and menthol to appeal to health-conscious demographics who value holistic wellness alongside symptomatic relief. This strategic pivot toward nature-derived efficacy is generating tangible financial gains for major industry players; Sanofi's Consumer Healthcare division, for example, reported a 9.6% sales increase in its July 2024 earnings release, a performance significantly driven by the double-digit growth of Qunol, a leading turmeric-based health brand.

Key Market Players

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services Inc
  • GSK plc
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • Merck & Co Inc.

Report Scope

In this report, the Global Over-the-Counter (OTC) Analgesics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over-the-Counter (OTC) Analgesics Market, By Drug Type

  • Acetaminophen
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Salicylates and Other Analgesics

Over-the-Counter (OTC) Analgesics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Over-the-Counter (OTC) Analgesics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over-the-Counter (OTC) Analgesics Market.

Available Customizations:

Global Over-the-Counter (OTC) Analgesics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Over-the-Counter (OTC) Analgesics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Acetaminophen, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Salicylates and Other Analgesics)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Over-the-Counter (OTC) Analgesics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Over-the-Counter (OTC) Analgesics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Over-the-Counter (OTC) Analgesics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Over-the-Counter (OTC) Analgesics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Over-the-Counter (OTC) Analgesics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Over-the-Counter (OTC) Analgesics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Over-the-Counter (OTC) Analgesics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Over-the-Counter (OTC) Analgesics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Over-the-Counter (OTC) Analgesics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Over-the-Counter (OTC) Analgesics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Over-the-Counter (OTC) Analgesics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Over-the-Counter (OTC) Analgesics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Over-the-Counter (OTC) Analgesics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Over-the-Counter (OTC) Analgesics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Over-the-Counter (OTC) Analgesics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Johnson & Johnson Services Inc
  • 15.4. GSK plc
  • 15.5. Pfizer Inc.
  • 15.6. Sanofi SA
  • 15.7. Sun Pharmaceutical Industries Ltd.
  • 15.8. Takeda Pharmaceutical Company Limited
  • 15.9. AstraZeneca PLC
  • 15.10. Merck & Co Inc.

16. Strategic Recommendations

17. About Us & Disclaimer